Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
OBJECTIVE
To assess whether pegylated interferon alpha (PEG-IFNalpha) may induce peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus (HCV) infection.


METHODS
We studied 52 patients with HCV (38 men, 14 women; mean age 44.6 +/- 10.6 years) treated with IFNalpha. Before therapy (T(0)), patients underwent quantitative viral RNA determination, HCV genotype analysis, and neurologic and electrophysiologic evaluation. At the end (T(1)) and after therapy (T(2)), patients were neurologically and electrophysiologically re-evaluated. Antibodies to gangliosides and sulfatides were assayed by ELISA at T(0) and T(1). Twenty-three patients with HCV with comparable age, viral load, and genotype, not treated with IFNalpha, were studied as controls.


RESULTS
Seven patients (six in IFNalpha, one control) had peripheral neuropathy at recruitment. No significant differences in the electrophysiologic measures were detected between T(0) and T(1) (repeated-measures analysis of variance [ANOVA]) in any of the 52 patients or in those with neuropathy at T(0). No changes were found at T(2), independent of the viral response to treatment. Two patients, one with neuropathy, had antiganglioside antibodies at recruitment. Two patients, one not treated with IFNalpha, developed low antibody titers during follow-up, without symptoms or signs of neuropathy.


CONCLUSIONS
Pegylated interferon alpha therapy was not associated with the occurrence (or worsening) of peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus.
Briani
C
C
Department of Neurosciences, University of Padova, Italy. chiara.briani@unipd.it
Chemello
L
L
Zara
G
G
Ermani
M
M
Bernardinello
E
E
Ruggero
S
S
Toffanin
E
E
Gatta
A
A
Battistin
L
L
Cavalletto
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000378:metabolism; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005732:Gangliosides / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D009460:Neurologic Examination / Q000379:methods; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011446:Prospective Studies; D012367:RNA, Viral / Q000302:isolation & purification; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D013433:Sulfoglycosphingolipids / Q000276:immunology; D013997:Time Factors
D000906:Antibodies; D000998:Antiviral Agents; D005732:Gangliosides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D013433:Sulfoglycosphingolipids; D011092:Polyethylene Glycols; D012254:Ribavirin